期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 94, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2021.107501
关键词
mTOR-inhibitors; Lung transplantation; Immunosuppression
资金
- Broere Charitable Foundation
- KU Leuven University Chair - Medtronic
Among the lung transplant recipients included in this study, 13% received mTORi treatment, mostly due to renal insufficiency and malignancy. However, half of the patients discontinued mTORi therapy after experiencing adverse events or drug toxicity.
Mammalian target of rapamycin inhibitors (mTORi) are increasingly used after lung transplantation as part of a calcineurin inhibitor sparing regimen, aiming to preserve renal function. The aim of our study was to determine whether immunosuppressive therapy using mTORi in lung transplant recipients (LTR) is feasible in practice, or limited by intolerance and adverse events. Data were retrospectively assessed for all LTR transplanted between July 1991 and January 2020. Patients ever receiving mTORi (monotherapy or in combination with calcineurin inhibitor) as treatment of physicians? choice were included. 149/1184 (13%) of the LTR ever received mTORi. Main reasons to start were renal insufficiency (67%) and malignancy (21%). In 52% of the patients, mTORi was stopped due to side effects or drug toxicity after a median time of 159 days. Apart from death, main reasons for discontinuation were infection (19%) and edema (14%). Early discontinuation (<90 days) was mainly due to edema or gastrointestinal intolerance. As mTORi was stopped due to adverse events or drug intolerance in 52% of LTR, cautious consideration of advantages and disadvantages when starting mTORi is recommended.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据